REVIEW article
Front. Oncol.
Sec. Gastrointestinal Cancers: Gastric and Esophageal Cancers
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1650965
Comparative Analysis of Diagnostic Techniques and Treatment Modalities for Early-Stage Esophageal Carcinoma: A Comprehensive Review
Provisionally accepted
- 1Yangtze University, Jingzhou, China
- 2The First People's Hospital of Jingzhou, Jingzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Esophageal cancer (EC) is a significant global health burden, early disease management has witnessed substantial advancements in recent years. While surgical resection remains the cornerstone, emerging organ-preserving methods-including endoscopic resection (ER), definitive chemoradiotherapy (dCRT), and adjuvant therapies-are becoming viable alternatives for pT1a-m3/pT1b EC. This review critically evaluates contemporary diagnostic methods and emphasizes the critical role of advanced endoscopic techniques, such as Narrowband Imaging Magnifying Endoscopy (ME-NBI) in overcoming the challenge of sufficient recording for accurate TN staging.We systematically evaluated the treatment options for T1 lesions and compared the differences in survival outcomes, complications, and quality of life impact between ER, surgery, and chemoradiotherapy (CRT). Particular attention is given to the risk stratification of lymph node metastasis (LNM) and its impact on treatment selection. This review establishes an evidence-based risk stratification framework for LNM, informing clinical decision-making. ER is recommended for high-risk patients, while ER-CRT is an effective option for patients with lower recurrence risk.ER shows non-inferior survival to surgery with better functional outcomes (5-yr OS 90% vs 87%), while CRT provides organ preservation at higher stenosis risk (33%), per JCOG0502 and NCCN guidelines. By integrating data from key trials and current guidelines, this work clarifies ongoing controversies while highlighting emerging directions, including artificial intelligence(AI) enhanced endoscopic diagnosis and optimized adjuvant therapy. This analysis provides a comprehensive, evidence-based perspective for the rapidly developing field of gastrointestinal oncology.
Keywords: early esophageal cancer, Endoscopic resection, Surgery, Definitive chemoradiotherapy, Treatment advancements
Received: 20 Jun 2025; Accepted: 18 Aug 2025.
Copyright: © 2025 Liu, Zhang, Zhu, Tan, Luo, Liu and Zeng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Hai Zeng, The First People's Hospital of Jingzhou, Jingzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.